The mainstay of treatment for atrial fibrillation has historically been pharmacological, using drugs to control either the rhythm or the rate. However, nonpharmacological approaches have been effective at restoring sinus rhythm in drug-refractory patients, raising the possibility of using catheter ablation earlier in the management cascade than previously envisaged. Nonrandomized or single-center studies suggesting the superiority of catheter ablation over antiarrhythmic drug treatment have been reported. We performed a prospective randomized controlled trial involving 112 patients in 4 centers, 2 in North America and 2 in Europe, comparing a strategy of additional antiarrhythmic drugs (59 patients) with catheter ablation (53 patients) for patients with paroxysmal atrial fibrillation who had previously failed at least 1 antiarrhythmic drug. At the 1-year follow-up, 13 of 55 patients (23%) and 46 of 52 patients (89%) had no recurrence of atrial fibrillation in the antiarrhythmic drug and ablation groups, respectively (PϽ0.0001). Symptom score, exercise capacity, and quality-of-life scores were significantly higher in the ablation group. This multicenter randomized trial demonstrates that catheter ablation of atrial fibrillation is superior to antiarrhythmic drug therapy in patients with paroxysmal atrial fibrillation who have previously taken and failed antiarrhythmic drugs. The substantial improvement in quality of life, symptoms, and physical performance in this series of relatively young and healthy patients constitutes an important benefit that may support earlier use of catheter ablation in this context. See p 2498.
Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis: Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation)
Considerable interest has focused on the development of therapies that raise systemic levels of high-density lipoprotein (HDL) cholesterol. Despite substantial elevation of HDL cholesterol, the cholesteryl ester transfer protein inhibitor torcetrapib failed to slow progression of atherosclerosis and was associated with excess mortality in clinical trials. This has fueled speculation that the functionality of HDL is impaired in the setting of cholesteryl ester transfer protein inhibition. Although torcetrapib substantially elevated HDL cholesterol but had no effect on percent atheroma volume, in this post hoc analysis an inverse relationship was observed between changes in levels of HDL cholesterol and percent atheroma volume. Disease regression at the highest levels of HDL cholesterol suggests that HDL particles can retain their functional activity, in terms of lipid mobilization, in patients treated with cholesteryl ester transfer protein inhibitors. The lack of efficacy is likely to reflect some form of off-target toxicity, such as activation of the renin-angiotensin-aldosterone axis. As a result, additional cholesteryl ester transfer protein inhibitors that lack such adverse effects may have a beneficial influence on cardiovascular disease risk. This possibility requires confirmation in prospective randomized clinical trials. See p 2506.
Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity: A Pooled Analysis of the Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor (RADIANCE) Trials
The cholesteryl ester transfer protein (CETP) inhibitor torcetrapib has been shown to increase cardiovascular event rates despite conferring a significant high-density lipoprotein cholesterol increase. Hypotheses have been put forward to explain this unanticipated result, relating either to the mechanism of CETP inhibition per se or to off-target adverse effects of the torcetrapib molecule. We pooled the data from 2 large vascular imaging trials with torcetrapib and confirmed that the use of torcetrapib induces electrolyte changes, increase in blood pressure, and increased carotid intima-media thickness progression. The blood pressure changes were related to both the electrolyte changes and the increased carotid intima-media thickness progression. In contrast, torcetrapib-induced high-density lipoprotein increase was unrelated to either electrolyte changes or carotid intima-media thickness progression. The difference in carotid intima-media thickness progression between treatment groups was attenuated after adjustment for off-target effects (blood pressure and electrolyte changes) but not after adjustment for effects related to CETP inhibition (low-density lipoprotein cholesterol and highdensity lipoprotein cholesterol changes). Although it cannot be excluded that the mechanism of CETP inhibition was detrimental by itself, our findings suggest that off-target toxicity of the torcetrapib molecule has contributed to the adverse outcome seen with torcetrapib. Interactions with different types of antihypertensive medications suggest mineralocorticoid excess as a possible mechanism. Evidence is accumulating that other CETP inhibitors which are currently being developed do not display this type of off-target toxicity. Our study therefore supports a careful further development of these modalities, albeit with an unremittingly strong focus on their safety profile. See p 2515.
Angiotensin II Type 2 Receptor Stimulation: A Novel Option of Therapeutic Interference With the Renin-Angiotensin System in Myocardial Infarction?
Interference with the renin-angiotensin system is a very common, well-established, and successful concept of treatment in cardiovascular disease. All currently available and approved renin-angiotensin system-interfering drugs (angiotensin-converting enzyme [ACE] inhibitors, angiotensin II type 1 [AT 1 ] receptor [AT 1 R] blockers, renin inhibitors, aldosterone antagonists) aim at inhibition of the unfavorable effects of an overactivated renin-angiotensin system signaling via the AT 1 R. However, the renin-angiotensin system not only harbors the renin/ACE/AT 1 R-aldosterone axis, which, when overstimulated, is involved in a huge variety of pathologies ranging from hypertension to end-organ damage or local processes in myocardial infarction and stroke; in fact, it also possesses a tissueprotective axis involving ACE 2 , Ang 1-7 , and the AT 2 receptor (AT 2 R), which seems to counteract detrimental effects mediated via the AT 1 R but also inflammation, hyperproliferation, or fibrosis in general. At present, no pharmacological tool is available to specifically stimulate this beneficial ACE 2 /Ang 1-7 /AT 2 R axis in vivo. The novel nonpeptide AT 2 R agonist compound 21 may be such a drug. The study presented here is the first to test the therapeutic potential of direct AT 2 R stimulation in a model of myocardial infarction. Compound 21 significantly improved cardiac function and resulted
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Original Research Put Into Perspective for the Practicing Clinician Volume 118 Ⅲ Number 24 Ⅲ December 9, 2008 in a smaller scar size independent of any hemodynamic changes. Because compound 21 is a nonpeptide with a sufficient bioavailability (Ϸ30%), it may be a suitable lead compound for the development of a drug for the blood pressure-independent treatment or prevention of end-organ damage in humans. See p 2523.
Von Willebrand Factor, Type 2 Diabetes Mellitus, and Risk of Cardiovascular Disease: The Framingham Offspring Study
We tested whether elevated levels of the hemostatic and vascular dysfunction biomarker von Willebrand factor predicted incident cardiovascular disease in a community sample over 11 years of longitudinal follow-up, and in particular, among those with type 2 diabetes mellitus or insulin resistance (measured with the homeostasis model). After adjustment for age, sex, blood pressure, smoking, body mass index, total and high-density lipoprotein cholesterol, and treatment with aspirin, insulin, antihypertensives, and lipid-lowering medications, the hazard ratio for cardiovascular disease was 1.32 in the highest quartile of the von Willebrand factor distribution relative to the lowest (Pϭ0.04 for trend). Additional adjustment for type 2 diabetes mellitus or insulin resistance somewhat weakened the association. We stratified the models by diabetes status or the top quartile of the homeostasis model of insulin resistance distribution ("insulin resistant") versus the lower 3 quartiles. Von Willebrand factor was associated with cardiovascular disease among participants with diabetes mellitus (Pϭ0.04 for trend) but not among nondiabetics (Pϭ0.5) and similarly among insulin-resistant (Pϭ0.01) but not insulin-sensitive (Pϭ0.9) participants. Elevated levels of von Willebrand factor were an independent risk factor for cardiovascular disease, especially in people with diabetes mellitus or insulin resistance, in whom endothelial or hemostatic dysfunction may be a novel therapeutic target for prevention of cardiovascular disease. See p 2533.
Predictive Value of Myocardial Perfusion Single-Photon Emission Computed Tomography and the Impact of Renal Function on Cardiac Death
Although it is known that a substantial portion of death in patients with chronic kidney disease (CKD) is attributable to cardiac causes, risk-stratification methods in this group of patients have been less well described. In this study, we examine the impact of renal function on death rates and highlight the important role of singlephoton emission CT (SPECT) imaging in the risk stratification of patients with varying degrees of renal dysfunction. In this study population of 1652 predominately male patients, patients with CKD had higher death rates than those without CKD, and the same trend was seen for patients with an abnormal myocardial perfusion SPECT. Cardiac death was low in patients with normal scans and no CKD (0.8% per year). It rose more than 3-fold to 2.7% per year in CKD patients with no perfusion defects on myocardial perfusion SPECT and was substantially higher (9.5% per year) in patients with CKD and perfusion defects on myocardial perfusion SPECT. An abnormal myocardial perfusion SPECT and CKD in synergy predicted death more accurately than either one alone. Additionally, across the entire spectrum of renal function, myocardial perfusion abnormalities on SPECT were powerful predictors of cardiac death and all-cause mortality. The presence of ischemia, in particular, was independently associated with cardiac death, nonfatal myocardial infarction, and all-cause mortality. A CKD patient with an abnormal myocardial perfusion SPECT is in the highest risk group. The best route of management (invasive versus medical therapy) in this group of patients remains to be defined. Even in the presence of a normal SPECT, CKD confers risk that requires special attention to risk factor modification. See p 2540.
Gasping During Cardiac Arrest in Humans Is Frequent and Associated With Improved Survival
The incidence and significance of gasping after primary cardiac arrest are controversial. This study confirms that gasping is common in the early minutes after cardiac arrest, but in untreated patients its incidence decreases rapidly with time. Gasping was present in 33% of patients who arrested after emergency medical system arrival, in 20% when emergency medical system arrival was Ͻ7 minutes, in 14% when arrival time was 7 to 9 minutes, and in 7% when arrival time was Ͼ9 minutes. Among the patients who received bystander cardiopulmonary resuscitation, survival to hospital discharge occurred among 39% of patients who gasped versus only 9% who did not gasp. Thus, resuscitation efforts are most effective in patients who gasp. Gasping often delays the recognition of cardiac arrest in patients with witness collapse and thereby may delay prompt initiation of bystander resuscitation efforts. During resuscitation efforts, the return of gasping may be interpreted as a sign of recovery, so resuscitation efforts are often interrupted. Gasping is not a sign of recovery but a sign that resuscitation efforts are effective and should be continued because the chance of survival in such patients is greater. When gasping is present, assisted ventilation during resuscitation efforts might not be necessary. Recognition of gasping and its significance in patients with primary cardiac arrest is important to successful resuscitation efforts. See p 2550.
Plasma Fetuin-A Levels and the Risk of Myocardial Infarction and Ischemic Stroke
Fetuin-A is a protein almost exclusively secreted by the liver. Studies in humans have demonstrated that circulating fetuin-A levels are positively associated with fat accumulation in the liver, insulin resistance, the metabolic syndrome, and diabetes mellitus, conditions that are associated with increased risk of cardiovascular disease. Whether fetuin-A is associated with cardiovascular diseases in the general population is unknown. We evaluated the association of plasma fetuin-A concentrations with myocardial infarction and ischemic stroke on the basis of 395 subjects with myocardial infarction and stroke and 2198 individuals who remained free of cardiovascular events during follow-up. We observed that fetuin-A concentrations are strongly associated with risk of myocardial infarction and ischemic stroke independently of standard risk factors. Of note, some previous studies investigating the role of fetuin-A in cardiovascular diseases have yielded conflicting results. Low fetuin-A levels were associated with increased cardiovascular mortality in patients with end-stage renal disease. Because circulating fetuin-A is an inhibitor of calcification, increased vascular calcification in patients with renal disease (who display low fetuin-A levels) may be the mechanism underlying the observed association with increased mortality in this group of patients. Overall, these data and the present study indicate that the role of fetuin-A in cardiovascular diseases may be complex. Our data provide the first evidence for a link between high plasma fetuin-A levels and an increased risk of myocardial infarction and ischemic stroke. Additional research is warranted to elucidate the mechanisms by which fetuin-A influences the risk of cardiovascular disease. See p 2555.
Degradation and Healing Characteristics of Small-Diameter Poly(⑀-Caprolactone) Vascular Grafts in the Rat Systemic Arterial Circulation
Finding better shelf-ready small-diameter grafts has been on the agenda of many researchers and clinicians for decades. Currently available expanded polytetrafluoroethylene and Dacron grafts have a very limited use under 6 mm of internal diameter in cardiac and vascular surgery, mainly because of early thrombosis and late intimal hyperplasia. Biodegradable polymers have recently been investigated to serve as vascular scaffolds. After optimization studies, we produced biodegradable small-diameter scaffolds made of poly(⑀-caprolactone) nanofibers using electrospinning and implanted 15 poly(⑀-caprolactone) and 15 expanded polytetrafluoroethylene grafts (2-mm diameter, 13-mm length) with a follow-up of up to 6 months. Our results showed that these poly(⑀-caprolactone) grafts have significantly better healing characteristics such as faster endothelial coverage, better cellular infiltration accompanied by neoangiogenesis, and stable and homogeneous neointima formation com-pared with expanded polytetrafluoroethylene grafts. Rapid coverage of luminal surface by a confluent endothelium may prevent early graft thrombosis. In contrast to the expanded polytetrafluoroethylene grafts, which show increasing neointima formation and stenotic lesions over time, poly(⑀-caprolactone) grafts showed a more homogeneous neointimal layer covered by confluent endothelium. This may prevent late graft occlusions resulting from intimal hyperplasia. However, this hypothesis has to be tested by studies that have long-term follow-up in the arterial circulation of animals. Using biodegradable scaffolds, this study adds data to the fields of vascular prostheses and tissue engineering. Our promising results are a step toward the shelf-ready coronary bypass grafts of the future. See p 2563.
